Cited by 4,110Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Epidemiology of Parkinson's disease

de Lau, Lonneke ML, Breteler, Monique MB·2006·The Lancet Neurology

DOI 10.1016/s1474-4422(06)70471-9

Open this paper in CoChat — free account

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70471-9

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,777
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G., Widner, H., Mari�, R.-M., Rémy, P., & Levivier, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 863
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858

Show all 119 references

Research works printed but not linked: 3

Fink, 2001, Caffeine intake and the risk of incident Parkinson's disease: the Framingham Study, Mov Disord, 16, 984
Anderson, 1999, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord, 14, 21, 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y · DOI
De Lau LM, Koudstaal PJ, Witteman J, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology (in press).

Sorted by citations

Items 601–700 of 1,019

Technologies for Assessment of Motor Disorders in Parkinson’s Disease: A Review
Oung, Q. W., Muthusamy, H., Lee, H. L., Basah, S. N., Yaacob, S., Sarillee, M., & Lee, C. K. (2015) · Sensors · doi:10.3390/s150921710 · Cited by 70
Induced pluripotent stem cells: a tool for modeling Parkinson’s disease
Bose, A., Petsko, G. A., & Studer, L. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.05.001 · Cited by 74
Intracranial Applications of Magnetic Resonance-guided Focused Ultrasound
Lipsman, N., Mainprize, T. G., Schwartz, M. L., Hynynen, K., & Lozano, A. M. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0281-2 · Cited by 70
“PD is a heterogeneous motor disorder, characterized by progressive tremor, rigidity, akinesia, and postural instability [68].”
Background
Efficacy and safety of acupuncture for idiopathic Parkinson’s disease: a systematic review
Lam, Y. C., Kum, W. F., Durairajan, S. S. K., Lu, J. H., Man, S. C., Xu, M., Zhang, X. F., Huang, X. Z., & Li, M. (2008) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2007.0011 · Cited by 69
Impact of Selenium on Biomarkers and Clinical Aspects Related to Ageing. A Review
Alehagen, U., Opstad, T. B., Alexander, J., Larsson, A., & Aaseth, J. (2021) · Biomolecules · doi:10.3390/biom11101478 · Cited by 69
GLP-1 receptor agonists for Parkinson's disease
Mulvaney, C. A., Duarte, G. S., Handley, J. D., Evans, D. J., Menon, S., Wyse, R. K. H., & Emsley, H. C. A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012990.pub2 · Cited by 74
The Role of Lipids in the Initiation of α-Synuclein Misfolding
Kiechle, M., Grozdanov, V., & Danzer, K. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.562241 · Cited by 71
Caprylic acid ameliorates rotenone induced inflammation and oxidative stress in the gut-brain axis in Zebrafish
Cansız, D., Ünal, İ., Üstündağ, Ü. V., Alturfan, A. A., Altinoz, M. A., Elmacı, İ., & Emekli‐Alturfan, E. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06532-5 · Cited by 69
RETRACTED ARTICLE: Functional behavior of DHA and EPA in the formation of babies brain at different stages of age, and protect from different brain-related diseases
Khalid, W., Gill, P., Arshad, M. S., Ali, A., Ranjha, M. M. A. N., Mukhtar, S., Afzal, F., & Maqbool, Z. (2022) · International Journal of Food Properties · doi:10.1080/10942912.2022.2070642 · Cited by 70
Retracted
Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?
Logroscino, G., Urso, D., & Savica, R. (2022) · Neuroepidemiology · doi:10.1159/000525639 · Cited by 79
A generic optimization and learning framework for Parkinson disease via speech and handwritten records
Yousif, N. R., Balaha, H. M., Haikal, A. Y., & El-Gendy, E. M. (2022) · Journal of Ambient Intelligence and Humanized Computing · doi:10.1007/s12652-022-04342-6 · Cited by 69
Parkinson’s disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment
Prajjwal, P., Sanga, H. S. F., Acharya, K., Tango, T., John, J., Rodriguez, R. S. C., Marsool, M. D. M., Sulaimanov, M., Ahmed, A., & Hussin, O. A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001142 · Cited by 88
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease
Moreau, C., Meguig, S., Corvol, J., Labreuche, J., Vasseur, F., Duhamel, A., Delval, A., Bardyn, T., Devedjian, J.-C., Rouaix, N., et al. (2015) · Brain · doi:10.1093/brain/awv063 · Cited by 69
Analysis of surface EMG signal morphology in Parkinson's disease
Rissanen, S. M., Kankaanpaa, M. J., Tarvainen, M. P., Nuutinen, J., Tarkka, I. M., Airaksinen, O., & Karjalainen, P. A. (2007) · Physiological Measurement · doi:10.1088/0967-3334/28/12/005 · Cited by 69
“Parkinson’s disease (PD) is a neurodegenerative disorder that affects 1% of all people over 60 years of age in industrialized countries (De Lau and Breteler 2006).”
Background
A new modality for quantitative evaluation of Parkinson's disease: In-air movement
Drotár, P., Mekyska, J., Rektorová, I., Masárová, L., Smékal, Z., & Faúndez-Zanuy, M. (2013) · IEEE International Conference on Bioinformatics and Bioengineering (BIBE) · doi:10.1109/bibe.2013.6701692 · Cited by 69
“PD usually affects people with the average age of 60, although 5% to 10% of patients may develop symptoms even before age 40 [1].”
Background
Deprenyl prevents MPP+-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk
Xiao, H., Lv, F., Xu, W., Zhang, L., Jing, P., & Cao, X. (2011) · Toxicology · doi:10.1016/j.tox.2011.10.007 · Cited by 70
Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007
Bronstein, J. M., Carvey, P. M., Chen, H., Cory‐Slechta, D. A., Monte, D. A. D., Duda, J. E., English, P. B., Goldman, S. M., Grate, S. J., Hansen, J., et al. (2008) · Environmental Health Perspectives · doi:10.1289/ehp.11702 · Cited by 75
Obstructive Sleep Apnea and Cognition in Parkinson's disease
Harmell, A. L., Neikrug, A. B., Palmer, B. W., Avanzino, J. A., Liu, L., Maglione, J. E., Natarajan, L., Corey‐Bloom, J., Loredo, J. S., & Ancoli‐Israel, S. (2016) · Sleep Medicine · doi:10.1016/j.sleep.2016.01.001 · Cited by 69
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting approximately 1% of individuals over the age of 60 years old and 4% of adults over the age of 80 [1].”
Background
Trends in the Incidence of Parkinson Disease in the General Population
Darweesh, S. K. L., Koudstaal, P. J., Stricker, B. H. C., Albert Hofman, D., & Ikram, M. A. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv271 · Cited by 69
Cognitive and Psychiatric Effects of STN versus GPi Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials
Wang, J., Zhang, Y., Zhang, X.-H., Wang, Y., Li, J.-P., & Li, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156721 · Cited by 69
Melanin and neuromelanin binding of drugs and chemicals: toxicological implications
Karlsson, O., & Lindquist, N. G. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1757-0 · Cited by 73
Loss of nuclear REST/NRSF in aged-dopaminergic neurons in Parkinson’s disease patients
Kawamura, M., Sato, S., Matsumoto, G., Fukuda, T., Shiba‐Fukushima, K., Noda, S., Takanashi, M., Mori, N., & Hattori, N. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.042 · Cited by 74
“It is predicted that PD affects over 1% of the population at age 60, but the rate of PD is five times higher by age 80, suggesting that senescence of the brain or neurons is related to the onset of PD [2] [9] [16].”
Contribution of language studies to the understanding of cognitive impairment and its progression over time in Parkinson’s disease
Auclair‐Ouellet, N., LIEBERMAN, P. H., & Monchi, O. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.014 · Cited by 74
“For a majority of PD patients, genetic causes do not seem to have a primary role in the development of the disease (de Lau and Breteler, 2006).”
Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes
Crosiers, D., Theuns, J., Cras, P. P., & Broeckhoven, C. V. (2011) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2011.07.003 · Cited by 70
“All rights reserved. doi:10.1016/j.jchemneu.2011.07.003 age 85 (De Lau and Breteler, 2006).”
Influential
MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates
Morin, N., Grégoire, L., Morissette, M., Desrayaud, S., Gomez‐Mancilla, B., Gasparini, F., & Paolo, T. D. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.036 · Cited by 68
Initial management of Parkinson's disease
Goetz, C. G., & Pal, G. D. (2014) · BMJ · doi:10.1136/bmj.g6258 · Cited by 72
Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson's disease
Garg, A., Appel‐Cresswell, S., Popuri, K., McKeown, M. J., & Beg, M. F. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00101 · Cited by 68
Identifying clinical measures that most accurately reflect the progression of disability in Parkinson disease
Ellis, T. D., Cavanaugh, J. T., Earhart, G. M., Ford, M. P., Foreman, K. B., Thackeray, A., Thiese, M. S., & Dibble, L. E. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.02.006 · Cited by 73
“several years [2].”
Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson’s disease
Hare, D. J., Cardoso, B. R., Raven, E. P., Double, K. L., Finkelstein, D. I., Szymlek‐Gay, E. A., & Biggs, B. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-016-0004-y · Cited by 68
A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers
Yang, S., Beavan, M. S., Chau, K., Taanman, J., & Schapira, A. H. V. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.011 · Cited by 73
Neuromodulation of Glial Function During Neurodegeneration
Stevenson, R., Samokhina, E., Rossetti, I., Morley, J. W., & Buskila, Y. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00278 · Cited by 72
Global Characterization of Peripheral B Cells in Parkinson’s Disease by Single-Cell RNA and BCR Sequencing
Wang, P., Luo, M., Zhou, W., Jin, X., Xu, Z., Yan, S., Li, Y., Xu, C., Cheng, R., Huang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.814239 · Cited by 68
Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
Fröhlich, H., Bontridder, N., Petrovska‐Delacrétaz, D., Glaab, E., Kluge, F., El‐Yacoubi, M. A., Valero, M. M., Corvol, J., Eskofier, B. M., Gyseghem, J.-M. V., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.788427 · Cited by 69
Tear Biomarkers in Alzheimer’s and Parkinson’s Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review)
Król-Grzymała, A., Sienkiewicz‐Szłapka, E., Fiedorowicz, E., Rozmus, D., Cieślińska, A., & Grzybowski, A. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710123 · Cited by 74
Bent out of shape: α‐Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease
Luna, E., & Luk, K. C. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.023 · Cited by 67
EchoWear
Dubey, H., Goldberg, J. C., Abtahi, M., Mahler, L. A., & Mankodiya, K. (2015) · Wireless Health · doi:10.1145/2811780.2811957 · Cited by 67
“ase; smartwatch; speech therapy; wearable system. I. INTRODUCTION Parkinson disease (PD) is the second most common neurodegenerative disorder of mid-to-late life in developing and developed countries [1]. Approximately 4 million people worldwide were diagnosed with PD in 2005 and that number projected to go beyond 9 m…”
Background
Predicting Parkinson's disease – why, when, and how?
Postuma, R. B., & Montplaisir, J. Y. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70793-x · Cited by 67
“5% to only 4% [2,3].”
Sleep disordered breathing in Parkinson's disease: A critical appraisal
da Silva‐Júnior, F. P., do Prado, G. F., Barbosa, E. R., Tufik, S., & Togeiro, S. M. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2013.04.005 · Cited by 67
Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson’s Disease
Nam, M., Park, M., Park, H., Kim, Y., Yoon, S.-K., Sawant, V. S., Choi, J. W., Park, J., Park, K. D., Min, S., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00050 · Cited by 67
Effects of Resistance Training on Measures of Muscular Strength in People with Parkinson’s Disease: A Systematic Review and Meta-Analysis
Roeder, L., Costello, J. T., Smith, S. S., Stewart, I. B., & Kerr, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132135 · Cited by 67
“PD is more prevalent in older age groups with a rapid increase of cases after the age of 60 [3,4].”
Background
Validity and inter-rater reliability of inertial gait measurements in Parkinson's disease: A pilot study
Esser, P., Dawes, H., Collett, J., Feltham, M. G., & Howells, K. (2012) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2012.01.005 · Cited by 67
RETRACTED ARTICLE: Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation
Peng, T., Liu, X., Wang, J., Liu, Y., Fu, Z., Ma, X., Li, J., Sun, G., Ji, Y., Lu, J., et al. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1636805 · Cited by 66
Retracted
Peripheral electrical stimulation to reduce pathological tremor: a review
Pascual-Valdunciel, A., Hoo, G. W., Avrillon, S., Barroso, F. O., Goldman, J. G., Hernandez-Pavon, J. C., & Pons, J. L. (2021) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-021-00811-9 · Cited by 66
Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation
Willems, S., Zaienne, D., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00186 · Cited by 66
The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study.
Seifert, K. D., & Wiener, J. I. (2013) · Europe PMC (PubMed Central) · Cited by 66
Genetic screens in Caenorhabditis elegans models for neurodegenerative diseases
Sin, O., Michels, H., & Nollen, E. A. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.01.015 · Cited by 72
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines
Zádori, D., Klivènyi, P., Plangár, I., Toldi, J., & Vécsei, L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01237.x · Cited by 68
Levodopa in Parkinson's disease: from the past to the future
Pezzoli, G., & Zini, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003598919 · Cited by 66
Impulsive and Compulsive Behaviors in Parkinson's Disease
Averbeck, B. B., O’Sullivan, S. S., & Djamshidian, A. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153705 · Cited by 73
Environmental Toxicants-Induced Immune Responses in the Olfactory Mucosa
Imamura, F., & Hasegawa‐Ishii, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00475 · Cited by 68
Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson’s disease
Schutt, C. R., Gendelman, H. E., & Mosley, R. L. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0255-7 · Cited by 64
Recent progress in therapeutic strategies for microglia-mediated neuroinflammation in neuropathologies
Gupta, N., Shyamasundar, S., Patnala, R., Karthikeyan, A., Arumugam, T. V., Ling, E., & Dheen, S. T. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1515917 · Cited by 67
The neuroprotective effect of schisandrol A on 6-OHDA-induced PD mice may be related to PI3K/AKT and IKK/IκBα/NF-κB pathway
Yan, T., Sun, Y., Gong, G., Li, Y., Fan, K., Wu, B., Bi, K., & Jia, Y. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110743 · Cited by 66
Assessment of copper, iron, zinc and manganese status and speciation in patients with Parkinson’s disease: A pilot study
Ajsuvakova, O. P., Tinkov, A. A., Willkommen, D., Skalnaya, A. A., Danilov, A. B., Pilipovich, A. A., Aschner, M., Skalny, A. V., Michalke, B., & Геннадиевна, С. М. (2019) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2019.126423 · Cited by 67
Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys
Morin, N., Morissette, M., Grégoire, L., Gomez‐Mancilla, B., Gasparini, F., & Paolo, T. D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.028 · Cited by 65
Chronic renal dysfunction, proteinuria, and risk of Parkinson's disease in the elderly
Nam, G. E., Kim, N. H., Han, K., Choi, K. M., Chung, H. S., Kim, J. W., Han, B., Cho, S.-J., Jung, S. J., Yu, J. H., et al. (2019) · Movement Disorders · doi:10.1002/mds.27704 · Cited by 64
Neuroprotective benefits of grape seed and skin extract in a mouse model of Parkinson’s disease
Youssef, S. B., Brisson, G. J., Doucet-Beaupré, H., Castonguay, A.-M., Gora, C., Amri, M., & Lévesque, M. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1616435 · Cited by 65
Respiratory disorders of Parkinson’s disease
Aquino, Y. C., Cabral, L. M., Miranda, N. C., Naccarato, M. C., Falquetto, B., Moreira, T. S., & Takakura, A. C. T. (2021) · Journal of Neurophysiology · doi:10.1152/jn.00363.2021 · Cited by 69
Management of constipation in Parkinson’s disease
Rossi, M., Merello, M., & Perez‐Lloret, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.997211 · Cited by 68
alpha-Synuclein and intracellular trafficking: impact on the spreading of Parkinson’s disease pathology
Eisbach, S. E., & Outeiro, T. F. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1038-9 · Cited by 65
Estimating the direct and indirect costs associated with Parkinson’s disease
Rodríguez‐Blázquez, C., Forjaz, M. J., Lizán, L., Paz, S., & Martínez‐Martín, P. (2015) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.1103184 · Cited by 65
Tianma Gouteng Yin, a Traditional Chinese Medicine decoction, exerts neuroprotective effects in animal and cellular models of Parkinson’s disease
Liu, L., Song, J., Lu, J., Huang, Y., Zeng, Y. X., Chen, L., Durairajan, S. S. K., Han, Q., & Li, M. (2015) · Scientific Reports · doi:10.1038/srep16862 · Cited by 70
Effects of 2 Years of Exercise on Gait Impairment in People With Parkinson Disease: The PRET-PD Randomized Trial
Rafferty, M. R., Prodoehl, J., Robichaud, J. A., David, F. J., Poon, C., Goelz, L. C., Vaillancourt, D. E., Kohrt, W. M., Comella, C. L., & Corcos, D. M. (2016) · Neurology Report · doi:10.1097/npt.0000000000000163 · Cited by 65
“This produced 4 walking conditions: (1) off-medication comfortable speed, (2) off-medication fast speed, (3) on-medication comfortable speed, and (4) onmedication fast speed.”
Method
miR-494-3p modulates the progression of in vitro and in vivo Parkinson’s disease models by targeting SIRT3
Geng, L., Zhang, T., Liu, W., & Chen, Y. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.03.037 · Cited by 65
Cognitive Flexibility Deficits Following 6-OHDA Lesions of the Rat Dorsomedial Striatum
Grospe, G. M., Baker, P. M., & Ragozzino, M. E. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.032 · Cited by 65
New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease
Ekimova, I. V., Плаксина, Д. В., Pastukhov, Y. F., Lapshina, K. V., Lazarev, V. F., Mikhaylova, E. R., Полоник, С. Г., Pani, B., Margulis, B. A., Guzhova, I. V., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.04.012 · Cited by 65
CHARACTERIZATION BY FRACTAL DIMENSION ANALYSIS OF THE RETINAL CAPILLARY NETWORK IN PARKINSON DISEASE
Shi, C., Chen, Y., Kwapong, W. R., Tong, Q., Wu, S., Zhou, Y., Miao, H., Shen, M., & Ye, H. (2019) · Retina · doi:10.1097/iae.0000000000002641 · Cited by 65
Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson’s Disease is Mediated by α7-Nicotinic Receptors
Nebrisi, E. E., Javed, H., Ojha, S. K., Öz, M., & Shehab, S. A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197329 · Cited by 70
“3% of people of all ages in industrialized countries [2].”
Background
Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders
McOmish, C. E., & Hannan, A. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.7.899 · Cited by 66
Neurodegenerative diseases – Understanding their molecular bases and progress in the development of potential treatments
Rowińska‐Żyrek, M., Salerno, M., & Kozłowski, H. (2014) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.03.026 · Cited by 66
Schinus terebinthifolius Essential Oil Attenuates Scopolamine-Induced Memory Deficits via Cholinergic Modulation and Antioxidant Properties in a Zebrafish Model
Todirașcu-Ciornea, E., El‐Nashar, H. A. S., Mostafa, N. M., Eldahshan, O. A., Boiangiu, R. Ş., Dumitru, G., Hriţcu, L., & Singab, A. N. B. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/5256781 · Cited by 70
Trends in Mortality From Parkinson Disease in the United States, 1999–2019
Rong, S., Xu, G., Liu, B., Sun, Y., Snetselaar, L. G., Wallace, R. B., Li, B., Liao, J., & Bao, W. (2021) · Neurology · doi:10.1212/wnl.0000000000012826 · Cited by 64
Solid-State 13C NMR Reveals Annealing of Raft-Like Membranes Containing Cholesterol by the Intrinsically Disordered Protein α-Synuclein
Leftin, A., Job, C., Beyer, K., & Brown, M. F. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.04.002 · Cited by 64
Tom70 Is Essential for PINK1 Import into Mitochondria
Kato, H., Lu, Q., Rapaport, D., & Kozjak‐Pavlovic, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058435 · Cited by 64
Role of SIRT1 in autoimmune demyelination and neurodegeneration
Martin, A., Tegla, C., Cudrici, C. D., Kruszewski, A. M., Azimzadeh, P. N., Boodhoo, D., Mekala, A. P., Rus, V., & Rus, H. (2014) · Immunologic Research · doi:10.1007/s12026-014-8557-5 · Cited by 67
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1 % of the population over 60 years of age in industrialized countries [98].”
Background
Lentiviral Delivery of LMX1a Enhances Dopaminergic Phenotype in Differentiated Human Bone Marrow Mesenchymal Stem Cells
Barzilay, R., Ben‐Zur, T., Bulvik, S., Melamed, E., & Offen, D. (2008) · Stem Cells and Development · doi:10.1089/scd.2008.0138 · Cited by 64
Epidemiology of complementary and alternative medicine use in patients with Parkinson’s disease
Wang, Y., Xie, C., Wang, W., Lü, L., Fu, D.-L., Wang, X., & Zheng, G. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.10.022 · Cited by 64
Insights on altered mitochondrial function and dynamics in the pathogenesis of neurodegeneration
McInnes, J. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-12 · Cited by 65
Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
Smith, G. A., Jansson, J. P., Rocha, E. M., Osborn, T. M., Hallett, P. J., & Ole Isacson, A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9435-4 · Cited by 67
Association Between the Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson's Disease: A HuGE Review and Meta-Analysis
Ragland, M. F., Hutter, C., Zabetian, C. P., & Edwards, K. L. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp288 · Cited by 64
S erum 25‐hydroxyvitamin D concentrations in Mid ‐adulthood and P arkinson's disease risk
Shrestha, S., Lutsey, P. L., Alonso, Á., Huang, X., Mosley, T. H., & Chen, H. (2016) · Movement Disorders · doi:10.1002/mds.26573 · Cited by 64
Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson’s Disease: Correlation between Plasma and Cerebrospinal Fluid Levels
Horváth, I., Iashchishyn, I. A., Forsgren, L., & Morozova‐Roche, L. A. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00063 · Cited by 64
Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies
Caplan, I. F., & Maguire‐Zeiss, K. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00417 · Cited by 68
Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland
Fleury, V., Brindel, P., Nicastro, N., & Burkhard, P. R. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.03.030 · Cited by 68
A multiple treatment comparison meta‐analysis of monoamine oxidase type B inhibitors for Parkinson's disease
Binde, C. D., Tvete, I. F., Gåsemyr, J., Natvig, B., & Klemp, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13651 · Cited by 64
In vivo, in vitro and pharmacologic models of Parkinson's disease
Salari, S., & Bagheri, M. (2019) · Physiological Research · doi:10.33549/physiolres.933895 · Cited by 64
“Recent investigations on this substance have examined the development of PD and higher intake of vitamin B (de Lau and Breteler 2006).”
BackgroundInfluential
Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson’s disease rat model
Park, H. W., Park, C. G., Park, M. J., Lee, S. H., Park, H. R., Lim, J., Paek, S. H., & Choy, Y. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-66493-w · Cited by 67
“In this work, we prepared five distinct animal groups, depending on treatment: (1) no treatment (animals without treatment, n = 3), (2) oral CoQ10 (animals treated with oral administration of CoQ10, n = 3), (3) Alzet-PBS (animals treated with an Alzet pump filled with PBS only, n = 3), (4) Alzet-low CoQ10 (animals tre…”
Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis
Feng, F., Cai, Y., Hou, Y., Ou, R., Jiang, Z., & Shang, H. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.02.016 · Cited by 66
Feasibility Study of a Wearable System Based on a Wireless Body Area Network for Gait Assessment in Parkinson's Disease Patients
Cancela, J., Pastorino, M., Arredondo, M., Nikita, K., Villagra, F., & Pastor, M. (2014) · Sensors · doi:10.3390/s140304618 · Cited by 63
Circadian dysregulation in Parkinson's disease
Videnovic, A., & Golombek, D. (2017) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2016.11.001 · Cited by 63
Detecting Motor Impairment in Early Parkinson’s Disease via Natural Typing Interaction With Keyboards: Validation of the neuroQWERTY Approach in an Uncontrolled At-Home Setting
Arroyo‐Gallego, T., Ledesma‐Carbayo, M. J., Butterworth, I., Matarazzo, M., Montero‐Escribano, P., Puertas‐Martín, V., Gray, M. L., Giancardo, L., & Sánchez‐Ferro, Á. (2018) · Journal of Medical Internet Research · doi:10.2196/jmir.9462 · Cited by 65
“3% of the general population and about 1% in people over 60 years [1].”
Background
LncRNA H19 Attenuates Apoptosis in MPTP-Induced Parkinson’s Disease Through Regulating miR-585-3p/PIK3R3
Zhang, Y., Xia, Q., & Lin, J. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03035-w · Cited by 63
New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
Kibret, B. G., Ishiguro, H., Horiuchi, Y., & Onaivi, E. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020975 · Cited by 69
Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson’s disease
Irmady, K., Hale, C. R., Qadri, R., Fak, J. J., Simelane, S., Carroll, T., Przedborski, S., & Darnell, R. B. (2023) · Nature Communications · doi:10.1038/s41467-023-39652-6 · Cited by 63
Pesticides, Microglial NOX2, and Parkinson's Disease
Taetzsch, T., & Block, M. L. (2013) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21464 · Cited by 62
Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein
Janowska, M. K., Wu, K., & Baum, J. (2015) · Scientific Reports · doi:10.1038/srep15164 · Cited by 62
Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease
Devos, D., Lejeune, S., Cormier‐Dequaire, F., Tahiri, K., Charbonnier‐Beaupel, F., Rouaix, N., Duhamel, A., Sablonnière, B., Bonnet, A.-M., Bonnet, C., et al. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.10.017 · Cited by 63
“Parkinson’s disease (PD) is the second most frequent neurodegenerative disorder worldwide and affects more than 1% of the population over the age of 60 [1].”
Background
Salidroside protects against MPP+-induced apoptosis in PC12 cells by inhibiting the NO pathway
Li, X., Ye, X., Li, X., Sun, X., Liang, Q., Tao, L., Kang, X., & Chen, J. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.015 · Cited by 63
“Parkinson's disease (PD) is an old-age neurodegenerative disease, affecting more than 1% of humans over 60 years of age (De Lau and Breteler, 2006; Navarro et al., 2009).”
Background
Striatal shape in Parkinson's disease
Sterling, N. W., Du, G., Lewis, M. M., Dimaio, C., Kong, L., Eslinger, P. J., Styner, M. A., & Huang, X. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.017 · Cited by 66

Authors: de Lau, L. M., & Breteler, M. M.
Affiliations: Erasmus MC (NL)
Corresponding author: Breteler, Monique MB
ORCID: Breteler, Monique MB
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2006-06
Volume: 5
Issue: 6
Pages: 525-535
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(06)70471-9
OpenAlex: W2134886133
Cited by: 4,110
References: 119
Citations by year: 2026: 108 · 2025: 172 · 2024: 229 · 2023: 230 · 2022: 307 · 2021: 315 · 2020: 337 · 2019: 290 · 2018: 301 · 2017: 284 · 2016: 259 · 2015: 288 · 2014: 232 · 2013: 200 · 2012: 159
FWCI: 7.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, prevalence, incidence, risk factors, prognosis, genetic susceptibility, gene-environment interaction, neurodegeneration, prospective cohort
MeSH terms: Age Factors, Humans, Parkinson Disease, Prognosis, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks